- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
The European Directorate for the Quality of Medicines & Health Care (EDQM) has issued a Certificate of Suitability for Mesalazine, enabling IOL Chemicals and Pharmaceuticals to export this product to European and other CEP-accepting countries. Mesalazine treats inflammatory bowel disease, potentially enhancing the company's market penetration and revenue streams. This certification signifies compliance with international quality standards, improving the company’s competitive position in the pharmaceutical sector. With these developments, keep an eye on how this expansion into new markets may influence growth and profitability moving forward.
All announcements from IOL Chemicals and Pharmaceuticals Limited